share_log

D: Filing D

D: Filing D

D:發行公告
美股SEC公告 ·  08/09 15:28

Moomoo AI 已提取核心訊息

FOXO Technologies, known in the stock market as FOXO.US, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) in Washington, D.C. The SEC has granted Notice of Effectiveness to the company on August 7, 2024, at 4:30 P.M. This notice pertains to the Form S-3, which is a registration form utilized by publicly traded companies for securities offerings. The effectiveness of this form indicates that FOXO Technologies has met the necessary SEC requirements to move forward with its securities offering. The company, originally named Vivos Therapeutics, Inc., is listed under the CIK number 0001716166 and has a file number of 333-281090 with the SEC.
FOXO Technologies, known in the stock market as FOXO.US, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) in Washington, D.C. The SEC has granted Notice of Effectiveness to the company on August 7, 2024, at 4:30 P.M. This notice pertains to the Form S-3, which is a registration form utilized by publicly traded companies for securities offerings. The effectiveness of this form indicates that FOXO Technologies has met the necessary SEC requirements to move forward with its securities offering. The company, originally named Vivos Therapeutics, Inc., is listed under the CIK number 0001716166 and has a file number of 333-281090 with the SEC.
FOXO技術在股票市場上被稱爲FOXO.US,在華盛頓特區的美國證券交易所(SEC)取得了重要進展。SEC於2024年8月7日下午4:30給予公司效力通知書。此通知涉及S-3表格,這是上市公司用於證券發行的登記表格。此表格的有效性表明FOXO Technologies已滿足向前推進證券發行的必要SEC要求。該公司最初名爲活力療法公司,列在CIk號碼0001716166下,與SEC的文件號碼爲333-281090。
FOXO技術在股票市場上被稱爲FOXO.US,在華盛頓特區的美國證券交易所(SEC)取得了重要進展。SEC於2024年8月7日下午4:30給予公司效力通知書。此通知涉及S-3表格,這是上市公司用於證券發行的登記表格。此表格的有效性表明FOXO Technologies已滿足向前推進證券發行的必要SEC要求。該公司最初名爲活力療法公司,列在CIk號碼0001716166下,與SEC的文件號碼爲333-281090。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息